UBS Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

UBS Group’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,781	Closed	-$11K	–	8373
2016 Q3	$11K	Sell	3,781 -7,015	-65%	-$12.2K	﹤0.01%	6758
2016 Q2	$16K	Buy	10,796 +10,021	+1,293%	+$22.9K	﹤0.01%	6489
2016 Q1	$3K	Sell	775 -8,056	-91%	-$49.9K	﹤0.01%	7260
2015 Q4	$89K	Sell	8,831 -11,147	-56%	-$134K	﹤0.01%	5311
2015 Q3	$272K	Buy	19,978 +19,053	+2,060%	+$339K	﹤0.01%	4391
2015 Q2	$17K	Sell	925 -1,450	-61%	-$31.4K	﹤0.01%	7053
2015 Q1	$62K	Sell	2,375 -5,588	-70%	-$142K	﹤0.01%	5854
2014 Q4	$167K	Buy	+7,963	New	+$201K	﹤0.01%	5215

UBS Group's AEGR Position: Q4 2016 in Review

UBS Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 3,781 shares — an estimated $11K sold.

UBS Group first reported a position in AEGR in Q4 2014 and held it in 8 quarters. The position peaked at $272K in Q3 2015. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

UBS Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
UBS Group sold 3,781 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $11K.
UBS Group first reported a position in Aegerion Pharmaceuticals in Q4 2014 and held it in 8 quarters.
UBS Group's Aegerion Pharmaceuticals position peaked at $272K in Q3 2015.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.